{
  "pmid": "39641926",
  "pmc_id": "11624585",
  "table": {
    "label": "Table 1.",
    "title": "Frequency of Genotype-Based Phenotypes and Recommended Dose Adjustments",
    "rows": [
      [
        "Patients treated with fluoropyrimidines and/or irinotecan a",
        "Control arm (n = 311), No. (%)",
        "Intervention arm (n = 252)"
      ],
      [
        "No. (%)",
        "Pharmacogenetic-informed treatment according to DPWG guidelines"
      ],
      [
        "Actionable genotype carriers",
        "23 (7.4)",
        "17 (6.7)",
        ""
      ],
      [
        "DPYD AS 0.5",
        "1 (0.3)",
        "0",
        "Avoid fluoropyrimidines or perform DPD phenotyping"
      ],
      [
        "DPYD AS 1",
        "6 (1.9)",
        "2 (0.8)",
        "50% of the standard dosage"
      ],
      [
        "DPYD AS 1.5",
        "7 (2.3)",
        "11 (4.4)",
        "50% of the standard dosage"
      ],
      [
        "UGT1A1 PM",
        "9 (2.9)",
        "4 (1.6)",
        "70% of the standard dosage"
      ],
      [
        "Nonactionable genotype carriers ( DPYD AS 2, UGT1A1 NM/IM)",
        "288 (92.6)",
        "235 (93.3)",
        "Standard dosage"
      ]
    ]
  }
}